Legend Biotech Files 6-K on FDA Briefing Books

Ticker: LEGN · Form: 6-K · Filed: Mar 13, 2024 · CIK: 1801198

Legend Biotech Corp 6-K Filing Summary
FieldDetail
CompanyLegend Biotech Corp (LEGN)
Form Type6-K
Filed DateMar 13, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: fda, regulatory-filing

TL;DR

Legend Biotech dropped FDA briefing books, signaling progress on drug development.

AI Summary

Legend Biotech Corporation filed a Form 6-K on March 13, 2024, reporting on the release of Sponsor and FDA Briefing Books. The company, incorporated in E9 with its principal executive office in Somerset, New Jersey, is a foreign private issuer that files annual reports under Form 20-F.

Why It Matters

This filing indicates ongoing communication and preparation with the FDA regarding potential drug approvals or reviews, which is a critical step in the pharmaceutical development process.

Risk Assessment

Risk Level: low — This is a routine filing providing information about FDA interactions, not a material event like a clinical trial failure or financial distress.

Key Players & Entities

  • Legend Biotech Corporation (company) — Registrant
  • 2101 Cottontail Lane Somerset, New Jersey 08873 (location) — Principal executive office address
  • March 13, 2024 (date) — Date of report
  • Form 6-K (document) — Filing type
  • Form 20-F (document) — Annual report form

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, used to furnish information to the SEC that the issuer makes or is required to make public in its home country.

What specific information is being reported in this 6-K?

This 6-K specifically reports on the release of Sponsor and FDA Briefing Books.

What is Legend Biotech Corporation's principal executive office address?

Legend Biotech Corporation's principal executive office is located at 2101 Cottontail Lane, Somerset, New Jersey 08873.

Does Legend Biotech file annual reports under Form 20-F or 40-F?

Legend Biotech indicates it files annual reports under cover of Form 20-F.

What is the filing date of this Form 6-K?

This Form 6-K was filed as of March 13, 2024.

Filing Stats: 300 words · 1 min read · ~1 pages · Grade level 12.5 · Accepted 2024-03-13 08:36:52

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LEGEND BIOTECH CORPORATION Date March 13, 2024 By s Ying Huang Name Ying Huang, Ph.D. Title Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.